Safinamide Mesylate API Application Granted Approval for Jinghua Pharmaceutical (002349.SZ)

Stock News

Oct 08

Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that its subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd. ("Nantong Company"), has received the Chemical API Marketing Application Approval Notice for Safinamide Mesylate issued by the National Medical Products Administration.

Safinamide Mesylate is an active pharmaceutical ingredient for anti-Parkinson's disease, primarily used in the treatment of Parkinson's disease.

The approval of this API marks that Nantong Company now holds the qualification to supply Safinamide Mesylate API in the domestic market, with the API registration status simultaneously transitioning to "A," allowing it to supply domestic formulation manufacturers for formulation filing and production use.

The receipt of the Chemical API Marketing Application Approval Notice for Safinamide Mesylate further enriches the company's API product pipeline, enhances its product portfolio, and is conducive to strengthening the company's market competitiveness in the specialty API sector, generating a positive impact on the company's future business development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1182200440"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182200440\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182200440?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-08 16:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182200440","market":"us","top_or_hot":-1,"title":"Safinamide Mesylate API Application Granted Approval for Jinghua Pharmaceutical (002349.SZ)","media":"Stock News","content":"<p>Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that its subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd. (\"Nantong Company\"), has received the Chemical API Marketing Application Approval Notice for Safinamide Mesylate issued by the National Medical Products Administration.<br><br>Safinamide Mesylate is an active pharmaceutical ingredient for anti-Parkinson's disease, primarily used in the treatment of Parkinson's disease.<br><br>The approval of this API marks that Nantong Company now holds the qualification to supply Safinamide Mesylate API in the domestic market, with the API registration status simultaneously transitioning to \"A,\" allowing it to supply domestic formulation manufacturers for formulation filing and production use.<br><br>The receipt of the Chemical API Marketing Application Approval Notice for Safinamide Mesylate further enriches the company's API product pipeline, enhances its product portfolio, and is conducive to strengthening the company's market competitiveness in the specialty API sector, generating a positive impact on the company's future business development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Safinamide Mesylate API Application Granted Approval for Jinghua Pharmaceutical (002349.SZ)</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSafinamide Mesylate API Application Granted Approval for Jinghua Pharmaceutical (002349.SZ)\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-10-08 16:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that its subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd. (\"Nantong Company\"), has received the Chemical API Marketing Application Approval Notice for Safinamide Mesylate issued by the National Medical Products Administration.<br><br>Safinamide Mesylate is an active pharmaceutical ingredient for anti-Parkinson's disease, primarily used in the treatment of Parkinson's disease.<br><br>The approval of this API marks that Nantong Company now holds the qualification to supply Safinamide Mesylate API in the domestic market, with the API registration status simultaneously transitioning to \"A,\" allowing it to supply domestic formulation manufacturers for formulation filing and production use.<br><br>The receipt of the Chemical API Marketing Application Approval Notice for Safinamide Mesylate further enriches the company's API product pipeline, enhances its product portfolio, and is conducive to strengthening the company's market competitiveness in the specialty API sector, generating a positive impact on the company's future business development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0102","symbol_name":"重组","start_time":0,"source_url":"","article_id":"1182200440","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182200440","pubTimestamp":1791448820,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that its subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd. (\"Nantong Company\"), has received the Chemical API Marketing...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK0102":"重组","BK0239":"医药制造","IPOS":"Renaissance International IPO ETF","002349":"精华制药"},"translate_title":"京华制药(002349.SZ)甲磺酸沙非酰胺原料药申请获批","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IPOS":1,"002349":1},"content_text":"Jinghua Pharmaceutical Group Co.,Ltd. (002349.SZ) has announced that its subsidiary, Jinghua Pharmaceutical Group Nantong Co., Ltd. (\"Nantong Company\"), has received the Chemical API Marketing Application Approval Notice for Safinamide Mesylate issued by the National Medical Products Administration.Safinamide Mesylate is an active pharmaceutical ingredient for anti-Parkinson's disease, primarily used in the treatment of Parkinson's disease.The approval of this API marks that Nantong Company now holds the qualification to supply Safinamide Mesylate API in the domestic market, with the API registration status simultaneously transitioning to \"A,\" allowing it to supply domestic formulation manufacturers for formulation filing and production use.The receipt of the Chemical API Marketing Application Approval Notice for Safinamide Mesylate further enriches the company's API product pipeline, enhances its product portfolio, and is conducive to strengthening the company's market competitiveness in the specialty API sector, generating a positive impact on the company's future business development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}